Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester LE5 4PW, UK.
Diabetes Complications Research Centre, Conway Institute, University College of Dublin, Dublin 4, Ireland.
Nutrients. 2021 Feb 26;13(3):762. doi: 10.3390/nu13030762.
Bariatric surgery is an effective intervention for management of obesity through treating dysregulated appetite and achieving long-term weight loss maintenance. Moreover, significant changes in glucose homeostasis are observed after bariatric surgery including, in some cases, type 2 diabetes remission from the early postoperative period and postprandial hypoglycaemia. Levels of a number of gut hormones are dramatically increased from the early period after Roux-en-Y gastric bypass and sleeve gastrectomy-the two most commonly performed bariatric procedures-and they have been suggested as important mediators of the observed changes in eating behaviour and glucose homeostasis postoperatively. In this review, we summarise the current evidence from human studies on the alterations of gut hormones after bariatric surgery and their impact on clinical outcomes postoperatively. Studies which assess the role of gut hormones after bariatric surgery on food intake, hunger, satiety and glucose homeostasis through octreotide use (a non-specific inhibitor of gut hormone secretion) as well as with exendin 9-39 (a specific glucagon-like peptide-1 receptor antagonist) are reviewed. The potential use of gut hormones as biomarkers of successful outcomes of bariatric surgery is also evaluated.
减重手术是通过治疗失调的食欲和实现长期体重维持来有效管理肥胖的一种干预手段。此外,在减重手术后观察到葡萄糖稳态的显著变化,包括在某些情况下,2 型糖尿病从术后早期缓解和餐后低血糖。在 Roux-en-Y 胃旁路术和袖状胃切除术(两种最常进行的减重手术)后早期,许多肠道激素的水平显著增加,并且它们被认为是术后观察到的饮食行为和葡萄糖稳态变化的重要介质。在这篇综述中,我们总结了人类研究中关于减重手术后肠道激素变化及其对术后临床结局影响的最新证据。通过使用奥曲肽(一种非特异性肠道激素分泌抑制剂)和 exendin 9-39(一种特异性胰高血糖素样肽-1 受体拮抗剂)评估减重手术后肠道激素在食物摄入、饥饿感、饱腹感和葡萄糖稳态方面的作用的研究也进行了综述。还评估了肠道激素作为减重手术成功结果的生物标志物的潜在用途。